Home Reflections on the Success of the Congress on Autoimmunity 2024: A Memorable Event

Latest news

This image is a promotional graphic for the MEDICA event. It shows the event's logo on the left and provides the key details on the right: the location is Düsseldorf, Germany, and the dates are November 17-20, 2025.
2025-11 / MEDICA 2025
The image shows a person dressed in a white medical coat, likely a doctor or healthcare professional, interacting with a futuristic, digital interface. The interface prominently displays the letters "AI" in the center, surrounded by various holographic graphics, charts, and icons related to health and technology. The person is pointing at the interface with their finger, as if engaging with the digital data. The background appears to be a modern hospital or medical facility, with medical equipment visible in the room.
AI in ANA Testing: A New Era in Autoimmune Diagnostics
Das Bild zeigt einen großen Konferenzraum, in dem zahlreiche Zuhörer einer Präsentation beiwohnen. Vorne befinden sich zwei Bildschirme, auf denen Folien gezeigt werden, ein Redner steht auf einem Podium und eine weitere Person sitzt neben ihm. Der Raum ist gut beleuchtet, durch die Fenster fällt etwas Tageslicht herein, und in der Nähe der Bühne stehen Blumenarrangements.
From Biomarkers to AI: Highlights of the 17th Dresden Symposium on Autoantibodies 2025
The picture shows a woman looking into a microscope. On the left side, there's a graphic of a test strip with multiple wells. Two arrows point to microscopic images showing the results of two different fixation methods: one for ethanol-fixed samples and one for formalin-fixed samples. The microscopic images show a green fluorescent pattern, which is characteristic of ANCA (anti-neutrophil cytoplasmic antibodies) testing.
ANCA dual: Two Targets, One Powerful Diagnostic Tool for ANCA-Associated Vasculitis
This image is a save-the-date announcement for the "17th Dresden Symposium on Autoantibodies," scheduled for September 9-12, 2025. It features a panoramic photo of the city of Dresden, Germany, with the Elbe river in the foreground and the historic skyline in the background. The website www.gfid-ev.de is also included.
2025-09 / Medipan & GA Generic Assays at 17. Dresdner Symposium on Autoantibodies (DSA)
This image shows a scene from the autoimmunity 2024. In the center, the main booth belongs to Medipan & GA Generic Assays. Three people are standing in front of it, smiling for the camera. The booth's banners display the companies' logos and the slogan "Your Partner in Autoimmune Diagnostic." There is also a sign advertising the "GA-Driver 2.0," an automated immunoassay analyzer. To the right, the booth for AROTEC Diagnostics Ltd. has a banner that identifies the company as a "GLOBAL LEADER IN AUTOIMMUNE ANTIGEN PURIFICATION." A man is standing at the front of their table. On the far left, another booth displays a large graphic of a human body with glowing points on it.
05.06.2024

Reflections on the Success of the Congress on Autoimmunity 2024: A Memorable Event

Medipan & GA Generic Assays at the 14th International Congress on Autoimmunity 2024 in Ljubljana

Some weeks ago, from May 17-19, 2024, we had the privilege of participating in the 14th International Congress on Autoimmunity in Ljubljana, Slovenia. This event brought together leading experts, researchers, and healthcare professionals to discuss the latest advancements in autoimmune diseases. The congress offered a forum to share updates and promote collaboration for consensus and standardization in autoimmunity diagnosis.

Congress Highlights

The congress was a dynamic forum covering key challenges and advances in diagnosing and treating autoimmune diseases. These included the most common diseases, with dedicated sections on lupus erythematosus, rheumatoid arthritis, and other autoimmune conditions. The congress covered numerous autoimmune diseases, including arthritis, myositis, antiphospholipid syndrome, systemic sclerosis, Sjögren syndrome, liver, GI diseases, and vasculitis. Additionally, novel autoimmune diseases, particularly the autoimmune syndrome induced by adjuvants (ASIA or Shoenfeld’s Syndrome), were discussed in depth.

Speakers presented a comprehensive overview of key diagnostic strategies, including sessions on the predictive value of autoantibodies in autoimmune conditions. They emphasized the latest research findings and their clinical implications. The 2023 ACR/EULAR Classification Criteria for Antiphospholipid Syndrome 1 were highlighted as a key reference point.

New insights were shared on SARS-CoV-2, COVID-19, and Post-COVID Syndrome in the context of autoimmunity.

Speakers discussed the treatment and management of autoimmune patients, emphasizing established therapies and introducing new applications, including big data, artificial intelligence, and ChatGPT.

Finally, the ICAP session focused on the clinical relevance of the HEp-2 IFA (ANA) test, with an anticipation of new ANA patterns in the nomenclature and classification tree2.

Networking and Collaboration

One of the most rewarding aspects of the congress was the opportunity to network with professionals from around the world. Informal discussions during breaks and meals led to the exchange of ideas and potential collaborations, underscoring the importance of such gatherings in advancing the field of autoimmunity.

Our Presence at the Congress

Our company proudly showcased a prominent presence at Autoimmunity 2024 with our own booth. The booth drew many attendees eager to explore our latest products and innovations in autoimmune disease diagnostics. Moreover, the event proved to be a fruitful platform for direct engagement with industry professionals, the opportunity to disseminate our latest advancements, and the receipt of invaluable feedback. The positive interactions and interest generated have further reinforced our commitment to advancing the field of autoimmunity.

Our Experience

Participating in the 14th International Congress on Autoimmunity proved to be an enriching experience. The event highlighted shared knowledge, innovative ideas, and a strong collaborative spirit throughout the proceedings.

Looking Forward

As we reflect on the success of Autoimmunity 2024, we are already looking forward to the next congress in 2026 in the wonderful city of Prague3. The progress made and connections formed during this event will undoubtedly contribute to the continued advancement of autoimmune disease research and treatment.

We extend our gratitude to the organizers, speakers, and fellow participants for their contributions to the success of Autoimmunity 2024.

References

  1. Barbhaiya et al. 2023 ACR/EULAR Antiphospholipid SyndromeClassification Criteria ↩︎
  2. International Consensus on Antinuclear Antibody (ANA) Patterns (ICAP) ↩︎
  3. 15th International Congress on Autoimmunity, 14-17 May, Prague, Czech Republic ↩︎